CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$ (11,006,794)	$ 35,948,698
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	426,440	23,780
Impairment of long-lived assets	99,519	0
Impairment of goodwill	188,069	0
Stock compensation expense	3,006,203	0
Loss on extinguishment of debt	16,000	0
Changes in fair value of contingent purchase consideration	(18,587,782)	(39,027,901)
Amortization of debt discount	3,121,569	0
Non-cash interest expense from issuance on debt (derivative)	959,976	0
Change in fair value of derivative liabilities - convertible notes	988,267	0
Change in fair value of derivative liabilities - convertible warrants	(28,215)	0
Change in fair value of derivative liabilities - downside protection	(3,085,502)	0
Bad debt expense	3,252,439	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(750,241)	(33,555)
Inventory	1,126,424	(2,040)
Accounts payable and accrued expenses	9,285,221	872,164
Accrued interest on notes receivable	1,387,763	0
Other current assets	49,248	(74,360)
Other assets, net	(22,797)	0
Net cash used in operating activities	(9,574,193)	(2,293,214)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(289,917)	(8,552)
Purchase of intangible assets	(26,487)	0
Disposal of property and equipment	292,681	0
Disposal of intangible assets	62,091	0
Cash received in acquisition of a business, net of cash paid	2,280,425	0
Net cash provided by (used in) investing activities	2,318,793	(8,552)
CASH FLOWS FROM FINANCING ACTIVITIES
Loan proceeds from related party	230,441	126,101
Payment of notes payable	(51,625)	0
Proceeds from note payable	6,329,910	0
Investment in subsidiary by noncontrolling interest	0	327,593
Net cash provided by financing activities	6,508,726	453,694
Effects of currency translation on cash and cash equivalents	(1,206)	15,272
Net increase (decrease) in cash and cash equivalents	(747,880)	(1,832,800)
Cash and cash equivalents, beginning of period	1,046,365	2,879,165
Cash and cash equivalents, end of period	298,485	1,046,365
Supplemental Disclosure of Cash Flow Information
Antigen dividend	0	320,000
Conversion of HDS debt and issuance of call option	14,056,113	0
Conversion of debt to equity	8,257,918	0
Exercise of call option	1,385,730	0
Issuance of warrants	5,592,244	0
Acquisition of Olaregen stock through issuance of common stock	2,000,000	0
Acquisition of Veneto through issuance of debt	0	0
Acquisition of Regentys through issuance of debt	0	0
Acquisition of Olaregen through issuance of debt	$ 0	$ 0